表紙
市場調査レポート

米国における関節内補充療法・軟骨、靭帯/腱および半月板修復・再生向け整形外科用バイオマテリアル市場

U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration

発行 Medtech Insight 商品コード 278601
出版日 ページ情報 英文 231 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
米国における関節内補充療法・軟骨、靭帯/腱および半月板修復・再生向け整形外科用バイオマテリアル市場 U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration
出版日: 2013年07月31日 ページ情報: 英文 231 Pages
概要

米国の関節内補充療法・軟骨、靭帯/腱および半月板修復・再生向け整形外科用バイオマテリアル市場額は、2017年に19億米ドルに達すると予測されています。

当レポートでは、米国の関節内補充療法・軟骨、靭帯/腱および半月板修復・再生向け整形外科用バイオマテリアル市場における製品、競合企業および機会についてセグメント別に分析しており、主要企業のプロファイルおよび今後の予測などを交え、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 筋骨格系の概要

  • 骨構造・機能
  • 関節構造・機能
  • 関節疾患の管理

第2章 成体吸収性固定装置

  • 材料
  • 製品
  • 市場分析
  • 競合分析

第3章 関節内補充療法

  • 変形性関節症の臨床概要
  • 関節内補充療法
  • 製品
  • 新興製品
  • 潜在的関節内補充療法患者
  • 製品の医療費償還
  • 市場分析
  • 競合分析

第4章 軟骨の修復・再生

  • 臨床概要
  • 製品
  • 医療費償還
  • 市場分析
  • 競合分析

第5章 半月板の修復・再生・置換え

  • 臨床概要
  • 現在の治療
  • 処置数
  • 半月板の修復・再生
  • 半月板の置換え
  • 開発中の半月板修復・再生・置換え技術
  • 全体市場予測

第6章 靭帯/腱の修復・再生・置換え

  • 臨床概要
  • 処置数
  • 現在の治療
  • 同種移植片
  • 組織工学
  • 成長因子
  • 細胞・遺伝子治療
  • 市場分析
  • 競合分析
  • 靭帯/腱置換え市場の状況
  • 新しい靭帯/腱の再生製品市場

第7章 企業プロファイル

  • Arthrex, Inc.
  • ConMed Linvatec/ConMed Corporation
  • Fidia Pharma USA, Inc./Fidia Farmaceutici SpA
  • Genzyme Corporation/Sanofi SA
  • Johnson & Johnson
  • LifeNet Health, Inc.
  • Medtronic, Inc.
  • Musculoskeletal Transplant Foundation, Inc.
  • RTI Biologics, Inc.
  • Smith & Nephew PLC

付録:企業リスト

目次
Product Code: A322

In the United States (U.S.), aging baby boomers are causing an increase in the prevalence of osteoarthritis and other degenerative joint disorders. In addition, the large and growing Millennial generation is contributing to an increasing number of sports-related injuries.

This dynamic new report from Medtech Insight includes analyses of products, competitors, and opportunities in the U.S. market for orthopedic biomaterials for viscosupplementation and cartilage, ligament/tendon, and meniscal repair and regeneration. This market, as covered by the scope of this report, comprises bioresorbable fixation devices (pins, screws, tacks, and suture anchors), cartilage repair and regeneration technologies (cell-based approaches, cell-free scaffolds, and gene therapy), ligament and tendon repair/replacement/ regeneration products (traditional sports medicine allografts and gene and cell-based therapies, platelet-rich plasma, scaffolds, and synthetic growth factors), meniscal repair/regeneration/replacement technologies (allografts, bioresorbable fixation devices, and scaffolding and cell therapy technologies), and viscosupplementation products (hyaluronic acid-based therapies). During the forecast period covered by this report, the combined U.S. market for orthopedic biomaterials for viscosupplementation and cartilage, ligament/tendon, and meniscal repair and regeneration is projected to reach an estimated value of $1.9 billion in the year 2017.

Table of Contents

EXECUTIVE SUMMARY

  • i. Bioresorbable Fixation Devices
  • ii. Viscosupplementation
  • iii. Cartilage Repair and Regeneration
  • iv. Meniscal Repair, Regeneration, and Replacement
    • a. Bioresorbable Fixation Devices
    • b. Meniscal Allografts
  • v. Ligament and Tendon Repair, Regeneration, and Replacement
  • vi. Combined Market Forecast
  • vii. Methodology
  • Exhibit ES-1: Types of Bioresorbable Fixation Devices
  • Exhibit ES-2: Bioresorbable Fixation Devices, Market Forecast, 2012-2017
  • Exhibit ES-3: Viscosupplementation Products, Market Forecast, 2012-2017
  • Exhibit ES-4: Cartilage Repair and Regeneration Products, Market Forecast, 2012-2017
  • Exhibit ES-5: Meniscal Repair, Regeneration, and Replacement Products, Combined Market Forecast, 2012-2017
  • Exhibit ES-6: Ligament and Tendon Allografts, Market Forecast, 2012-2017
  • Exhibit ES-7: Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration, Combined Market Forecast, 2012-2017

1. MUSCULOSKELETAL SYSTEM OVERVIEW

  • 1.1. Bone Structure and Function
    • 1.1.1. Cellular Framework
      • 1.1.1.1. Osteoblasts
      • 1.1.1.2. Osteocytes
      • 1.1.1.3. Osteoclasts
      • 1.1.1.4. Osteogenesis
    • 1.1.2. Bone Tissue
      • 1.1.2.1. Cancellous and Cortical Bone Tissue
      • 1.1.2.2. Bone Marrow
    • 1.1.3. Bone Anatomy
      • 1.1.3.1. Diaphysis and Epiphysis
      • 1.1.3.2. Endosteum
      • 1.1.3.3. Periosteum
    • 1.1.4. Joint Components
      • 1.1.4.1. Cartilage
        • 1.1.4.1.1. Elastic Cartilage
        • 1.1.4.1.2. Fibrocartilage
        • 1.1.4.1.3. Hyaline Cartilage
      • 1.1.4.2. Bursae
      • 1.1.4.3. Joint Cavity
      • 1.1.4.4. Menisci
      • 1.1.4.5. Synovial Membrane and Fluid
      • 1.1.4.6. Ligaments and Tendons
      • 1.1.4.7. Muscles
    • 1.1.5. Joint Structures
      • 1.1.5.1. Ankle
      • 1.1.5.2. Digits
      • 1.1.5.3. Elbow
      • 1.1.5.4. Hip
      • 1.1.5.5. Knee
      • 1.1.5.6. Shoulder
      • 1.1.5.7. Wrist
    • 1.1.6. Bone Formation and Remodeling
      • 1.1.6.1. In the Fetus
      • 1.1.6.2. In Childhood
      • 1.1.6.3. In Adulthood
      • 1.1.6.4. In Old Age
      • 1.1.6.5. Mechanical Stress and Wolff's Law
    • 1.1.7. Factors Affecting Bone Physiology
      • 1.1.7.1. Age
      • 1.1.7.2. Gender
      • 1.1.7.3. Genetic Disposition
      • 1.1.7.4. Hormonal Activity
      • 1.1.7.5. Physical Activity
      • 1.1.7.6. Cigarette Smoking
      • 1.1.7.7. Alcohol and Caffeine Intake
      • 1.1.7.8. Nutritional Deficiencies
  • 1.2. Joint Structure and Function
    • 1.2.1. Types of Joints
      • 1.2.1.1. Synarthroses
      • 1.2.1.2. Amphiarthroses
      • 1.2.1.3. Diarthroses
        • 1.2.1.3.1. Ball-and-Socket
        • 1.2.1.3.2. Condyloid
        • 1.2.1.3.3. Hinge
        • 1.2.1.3.4. Gliding
        • 1.2.1.3.5. Pivot
    • 1.2.2. Arthritis
      • 1.2.2.1. Osteoarthritis
      • 1.2.2.2. Rheumatoid Arthritis
  • 1.3. Management of Joint Disorders
    • 1.3.1. Joint Replacement
      • 1.3.1.1. Dislocation
      • 1.3.1.2. Ligament and Tendon Injuries
      • 1.3.1.3. Meniscal Injuries
  • Exhibit 1-1: Illustration of Bone Tissue
  • Exhibit 1-2: Types of Cartilage
  • Exhibit 1-3: Stages of Bone Remodeling

2. BIORESORBABLE FIXATION DEVICES

  • 2.1. Materials
  • 2.2. Products
    • 2.2.1. Bioresorbable Pins
    • 2.2.2. Bioresorbable Screws, Nails, and Tacks
    • 2.2.3. Bioresorbable Interference Screws
    • 2.2.4. Bioresorbable Suture Anchors
    • 2.2.5. Bioresorbable Meniscal Repair Devices
  • 2.3. Market Analysis
  • 2.4. Competitive Analysis
  • Exhibit 2-1: Advantages of Bioresorbable Fixation Devices
  • Exhibit 2-2: Factors Affecting the Properties of Bioresorbable Polymers
  • Exhibit 2-3: Types of Bioresorbable Fixation Devices
  • Exhibit 2-4: 2013, Selected Bioresorbable Pins
  • Exhibit 2-5: 2013, Selected Bioresorbable Nails, Screws, and Tacks
  • Exhibit 2-6: 2013, Selected Bioresorbable Interference Screws
  • Exhibit 2-7: 2013, Selected Bioresorbable Suture Anchors
  • Exhibit 2-8: 2013, Selected Bioresorbable Meniscal Repair Devices
  • Exhibit 2-9: Bioresorbable Fixation Devices, Market Forecast, 2012-2017
  • Exhibit 2-10: 2012, Bioresorbable Fixation Devices Market, Share by Supplier

3. VISCOSUPPLEMENTATION

  • 3.1. Osteoarthritis Clinical Overview
  • 3.2. Viscosupplementation Therapy
  • 3.3. Products
    • 3.3.1. Anika Therapeutics
    • 3.3.2. Ferring Pharmaceuticals
    • 3.3.3. Fidia Pharma USA/Fidia Farmaceutici
    • 3.3.4. Genzyme/Sanofi
    • 3.3.5. Seikagaku
    • 3.3.6. Smith & Nephew
  • 3.4. Emerging Products
  • 3.5. Potential Viscosupplementation Patients
  • 3.6. Product Reimbursement
  • 3.7. Market Analysis
  • 3.8. Competitive Analysis
  • Exhibit 3-1: 2013, Administerers of Hyaluronic Acid Injection Therapy, by Specialty
  • Exhibit 3-2: 2013, Selected Viscosupplementation Products
  • Exhibit 3-3: 2013, Selected Emerging Viscosupplementation Therapies
  • Exhibit 3-4: 2012, Patients with Knee Osteoarthritis
  • Exhibit 3-5: Projected Incidence of Symptomatic Knee Osteoarthritis, by 10-Year Age Group
  • Exhibit 3-6: Historical and Future Annual Growth Rates in the Elderly Population
  • Exhibit 3-7: Viscosupplementation Products, Market Forecast, 2012-2017
  • Exhibit 3-8: 2012, Viscosupplementation Products Market, Share by Supplier

4. CARTILAGE REPAIR AND REGENERATION

  • 4.1. Clinical Overview
  • 4.2. Products
    • 4.2.1. Cell-Based Approaches
      • 4.2.1.1. Chondrocyte Transplantation
        • 4.2.1.1.1. Anika Therapeutics
        • 4.2.1.1.2. BioTissue Technologies
        • 4.2.1.1.3. DePuy Mitek/Johnson & Johnson
        • 4.2.1.1.4. Geistlich Pharma
        • 4.2.1.1.5. Genzyme/Sanofi
        • 4.2.1.1.6. ProChon Biotech/Histogenics
        • 4.2.1.1.7. Sanofi
        • 4.2.1.1.8. TETEC/B. Braun Melsungen
        • 4.2.1.1.9. TiGenix
        • 4.2.1.1.10. Allogeneic Juvenile Chondrocytes
      • 4.2.1.2. Stem Cells
        • 4.2.1.2.1. Geron
        • 4.2.1.2.2. Medipost
        • 4.2.1.2.3. Mesoblast
        • 4.2.1.2.4. Smith & Nephew
      • 4.2.1.3. Growth Factor Technology
        • 4.2.1.3.1. BioMimetic Therapeutics/Wright Medical Group
        • 4.2.1.3.2. EMD Serono/Merck
        • 4.2.1.3.3. Sanofi
        • 4.2.1.3.4. TissueGene
    • 4.2.2. Cell-Free Composites and Scaffolds
      • 4.2.2.1. Anika Therapeutics
      • 4.2.2.2. Arthro Kinetics
      • 4.2.2.3. Biomet
      • 4.2.2.4. BioTissue
      • 4.2.2.5. Cartiva
      • 4.2.2.6. Cytex
      • 4.2.2.7. Histogenics
      • 4.2.2.8. Kensey Nash/Royal DSM
      • 4.2.2.9. Piramal Healthcare
      • 4.2.2.10. Regentis Biomaterials
      • 4.2.2.11. Smith & Nephew
  • 4.3. Reimbursement
  • 4.4. Market Analysis
  • 4.5. Competitive Analysis
  • Exhibit 4-1: The Outerbridge Classification System for Chondral Defects
  • Exhibit 4-2: Arthroscopic Knee Surgery, Procedure Volumes Forecast, 2012-2017
  • Exhibit 4-3: 2012, Cartilage Repair Procedures
  • Exhibit 4-4: Genzyme's Carticel Autologous Chondrocyte Implantation Device
  • Exhibit 4-5: 2013, Selected Chondrocyte Graft Products and Technologies
  • Exhibit 4-6: 2013, Selected Emerging Stem Cell-Based Products for Cartilage Repair
  • Exhibit 4-7: 2013, Selected Emerging Recombinant Human Growth Factor Products
  • Exhibit 4-8: 2013, Selected Cell-Free Scaffolds for Cartilage Repair and Regeneration
  • Exhibit 4-9: Cartilage Repair and Regeneration Products, Market Forecast, 2012-2017
  • Exhibit 4-10: Cartilage Regeneration, Potential Procedure Volumes Forecast, 2012-2017

5. MENISCAL REPAIR, REGENERATION, AND REPLACEMENT

  • 5.1. Clinical Overview
    • 5.1.1. Meniscal Injuries
      • 5.1.1.1. Traumatic Tears
      • 5.1.1.2. Degenerative Tears
  • 5.2. Current Treatment
    • 5.2.1. Nonoperative Treatment
    • 5.2.2. Surgical Treatment
      • 5.2.2.1. Arthroscopic Suturing
      • 5.2.2.2. Bioresorbable Fixation
      • 5.2.2.3. Meniscectomy
  • 5.3. Procedure Volumes
  • 5.4. Meniscal Repair and Regeneration
    • 5.4.1. Bioresorbable Fixation Products
    • 5.4.2. Market Analysis
    • 5.4.3. Competitive Analysis
  • 5.5. Meniscal Replacement
    • 5.5.1. Meniscal Allografts
    • 5.5.2. Market Analysis
    • 5.5.3. Competitive Analysis
  • 5.6. Meniscal Repair, Regeneration, and Replacement Technologies Under Development
    • 5.6.1. Scaffolding Technologies
      • 5.6.1.1. Collagen
      • 5.6.1.2. Fibrin
      • 5.6.1.3. Polymers
    • 5.6.2. Cell Therapy
  • 5.7. Combined Market Forecast
  • Exhibit 5-1: Anatomy of the Knee Joint
  • Exhibit 5-2: Common Types of Meniscal Tears
  • Exhibit 5-3: Illustration of a Meniscal Tear
  • Exhibit 5-4: Comparison of Treatment Options for Meniscal Injuries
  • Exhibit 5-5: Meniscectomy and Meniscal Repair, Procedure Volumes Forecast, 2012-2017
  • Exhibit 5-6: 2013, Selected Bioresorbable Fixation Devices for Meniscal Repair
  • Exhibit 5-7: Bioresorbable Fixation Devices for Meniscal Repair, Market Forecast, 2012-2017
  • Exhibit 5-8: 2012, Market for Bioresorbable Fixation Devices for Meniscal Repair, Share by Supplier
  • Exhibit 5-9: 2013, Selected Meniscal Allografts
  • Exhibit 5-10: Meniscal Allografts, Market Forecast, 2012-2017
  • Exhibit 5-11: 2012, Meniscal Allografts Products Market, Share by Supplier
  • Exhibit 5-12: 2013, Selected Meniscal Scaffolding Products Under Development
  • Exhibit 5-13: Chondrogen Phase I/II Clinical Trial Results
  • Exhibit 5-14: Meniscal Repair, Regeneration, and Replacement Products, Combined Market Forecast, 2012-2017

6. LIGAMENT AND TENDON REPAIR, REGENERATION, AND REPLACEMENT

  • 6.1. Clinical Overview
    • 6.1.1. The Knee
    • 6.1.2. The Achilles Tendon
    • 6.1.3. Hand Ligaments and Tendons
    • 6.1.4. Shoulder Ligaments and Tendons
  • 6.2. Procedure Volumes
  • 6.3. Current Treatments
    • 6.3.1. Anterior Cruciate Ligament Tears
    • 6.3.2. Rotator Cuff Tears
  • 6.4. Allografts
  • 6.5. Tissue Engineering
    • 6.5.1. Biologic Scaffolds
    • 6.5.2. Polymer-Based Scaffolds
  • 6.6. Growth Factors
    • 6.6.1. Platelet-Rich Plasma
    • 6.6.2. Synthetic Growth Factors
  • 6.7. Cell and Gene Therapies
    • 6.7.1. Cell-Based Therapies Under Development
  • 6.8. Market Analysis
  • 6.9. Competitive Analysis
  • 6.10. Ligament and Tendon Replacement Market Status
  • 6.11. Emerging Ligament and Tendon Regeneration Products Market
  • Exhibit 6-1: Anatomy of the Knee Joint
  • Exhibit 6-2: Anterior Cruciate Ligament Injury
  • Exhibit 6-3: Achilles Tendon Rupture
  • Exhibit 6-4: Ligaments of the Shoulder
  • Exhibit 6-5: 2012, Ligament and Tendon Procedures, by Anatomic Location
  • Exhibit 6-6: 2013, Selected Allografts for Ligament and Tendon Replacement
  • Exhibit 6-7: 2013, Selected Tissue-Engineered Ligament and Tendon Repair Products
  • Exhibit 6-8: 2013, Selected Collagen-Based Scaffolds Under Development for Ligament and Tendon Repair
  • Exhibit 6-9: 2013, Selected Synthetic Scaffolds Under Development for Ligament and Tendon Repair
  • Exhibit 6-10: Aperion Biologics' Z-Lig Xenograft
  • Exhibit 6-11: 2013, Selected Growth Factor Products and Technologies Under Development
  • Exhibit 6-12: 2013, Selected Cell-Based Therapy Approaches Under Development for Tendon Repair
  • Exhibit 6-13: Ligament and Tendon Allografts, Market Forecast, 2012-2017
  • Exhibit 6-14: 2012, Ligament and Tendon Allografts Market, Share by Supplier

7. COMPANY PROFILES

  • 7.1. Arthrex, Inc.
  • 7.2. ConMed Linvatec/ConMed Corporation
  • 7.3. Fidia Pharma USA, Inc./Fidia Farmaceutici SpA
  • 7.4. Genzyme Corporation/Sanofi SA
  • 7.5. Johnson & Johnson
  • 7.6. LifeNet Health, Inc.
  • 7.7. Medtronic, Inc.
  • 7.8. Musculoskeletal Transplant Foundation, Inc.
  • 7.9. RTI Biologics, Inc.
  • 7.10. Smith & Nephew PLC

APPENDIX: COMPANY LISTING

Back to Top